Next-generation sequencing (NGS) technology can be used for rare and undiagnosed disease research to discover causative variants of inherited disorders by assessing many genes at the same time. Using NGS can reduce costs compared to traditional methods, which are often expensive and inconclusive while requiring extensive testing.
Whole-exome and transcriptome sequencing prove beneficial in uncovering mutations and pathways associated with rare disease.Learn More
Of those, 80% have a genetic etiology, which may be uncovered with NGS and the TruSight One targeted panel.1-2 TruSight One is a targeted gene panel that uses NGS to simultaneously analyze up to 4813 genes associated with rare diseases.
The Blue Cross Blue Shield Association (BCBSA) technology review organization, known as Evidence Street®, issues review supporting whole-genome sequencing.Read Article
Landmark NGS study leads to a national clinical diagnostic exome sequencing platform in Singapore.Read Article
Families facing rare diseases can spend up to eight years pinpointing the problem in solitude – until now. See how hope and perserverence is uniting families.Read Article
The TruSight Software Suite is designed to help high-throughput labs call, prioritize, and report on variants associated with rare disease—all from one software interface.Learn More
Illumina offers cost-effective, streamlined, targeted NGS solutions that can empower your research into specific rare and undiagnosed diseases.
Perform NGS and cytogenomic array scanning all on one instrument with the NextSeq 550 System.
TruSight One Sequencing Panels target disease-associated regions of the exome with high analytical sensitivity and specificity.
The Illumina DRAGEN Bio-IT Platform facilitates rare disease research by enabling accurate, ultra-rapid secondary analysis of whole-genome and whole-exome sequencing data.3,4
Phosphorus uses the DRAGEN Bio-IT Platform to perform genomics data analysis onsite and at an accessible price point.Read Article